REG - Scancell Hlds - Scancell Appoints Sath Nirmalananthan as CFO

Scancell HoldingsAnnouncement

29/08/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230829:nRSc5469Ka&default-theme=true

RNS Number : 5469K  Scancell Holdings Plc  29 August 2023

            29 August 2023

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Scancell Appoints Sath Nirmalananthan as Chief Financial Officer

Keith Green to retire as Director of Finance but to remain as Company
Secretary

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for
the treatment of cancer and infectious disease, today announces the
appointment of Sath Nirmalananthan as Chief Financial Officer (CFO), with
immediate effect.

 

Sath Nirmalananthan is an experienced finance professional with over 15 years
experience across healthcare in FTSE and NASDAQ listed companies, investment
banking and audit. Before joining Scancell, Sath was Chief Financial Officer
for Europe, Middle-East and Africa at Prenetics, a leading genomics-driven
health sciences company. Prior to that, Sath worked at Reckitt where he was
Finance Director for Group Reporting and subsequently for eCommerce in
Reckitt's Health Division. Sath has also held senior positions at BTG plc, a
specialty pharmaceutical company, including Director of Group Reporting and
Director of FP&A of interventional oncology. Earlier in his career, he was
an equity research analyst in the healthcare team at Nomura and prior to that
an auditor at KPMG. Sath earned a BSc in Pharmacology from King's College,
London, UK and holds an ACA (ICAEW), Chartered Accountant qualification. Sath
is also a Non-Executive member of the audit committee at The Institute of
Cancer Research (ICR).

 

Prof Lindy Durrant, Chief Executive Officer of Scancell, commented: "We are
excited to have Sath join us as Chief Financial Officer. His financial acumen
and extensive track record of building value in emerging biopharmaceutical
companies will benefit Scancell in our next stage of evolution. I look forward
to working with him closely as we continue to focus the clinical development
of our two lead cancer vaccine assets, SCIB1 and Modi-1, whilst continuing to
leverage the potential of our proprietary antibody platform through additional
licensing and revenue generating opportunities. We are very grateful for
Keith's excellent financial guidance which has been invaluable to Scancell's
success to date and are pleased that he will continue as Company Secretary."

 

Commenting on his appointment as Chief Financial Officer, Sath Nirmalananthan
said: "I am excited to be joining Scancell at such a pivotal time. With the
Phase 2 single arm SCOPE trial progressing and initial topline data readouts
expected this year and Modi-1 next year, the Company is positioned with highly
valuable science and near-term inflection points that should deliver value to
our shareholders. I look forward to working with Lindy and the wider team and
am excited by the potential of what can be achieved."

 

 

 For further information, please contact:

 Scancell Holdings plc                                                        +44 (0) 20 3709 5700

 Professor Lindy Durrant, CEO

 Dr Jean-Michel Cosséry, Non-Executive Chairman

 Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)          +44 (0) 20 7710 7600
 Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment
 Banking)
 Nick Adams/Nick Harland (Corporate Broking)

 Panmure Gordon (UK) Limited (Joint Broker)                                   +44 (0) 20 7886 2500
 Freddy Crossley/Emma Earl (Corporate Finance)
 Rupert Dearden (Corporate Broking)

 Consilium Strategic Communications                                           +44 (0) 20 3709 5700
 Mary-Jane Elliott/Matthew Neal/Chris Welsh                                   scancell@consilium-comms.com (mailto:scancell@consilium-comms.com)

 

About Scancell

 

Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer and infectious disease. The Company is building a pipeline of
innovative products by utilising its four technology platforms: Moditope(®)
and ImmunoBody(®) for vaccines and GlyMab(®) and AvidiMab(®) for
antibodies.

 

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both
of which can recognise damaged or infected cells. In order to destroy such
cancerous or infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs.
The Company's unique approach is that its innovative products target
modifications of proteins and lipids. For the vaccines (Moditope(®) and
ImmunoBody(®)) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that are added
onto proteins and / or lipids (GlyMab(®)) or enhances the potency of
antibodies and their ability to directly kill tumour cells (AvidiMab(®)).

 

For further information about Scancell, please visit:
https://www.scancell.co.uk/ (https://www.scancell.co.uk/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFZGZRRRVGFZM